KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $793.7 million.

  • Alnylam Pharmaceuticals' Accumulated Expenses rose 21.93% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 21.93%. This contributed to the annual value of $793.7 million for FY2024, which is 11.32% up from last year.
  • Alnylam Pharmaceuticals' Accumulated Expenses amounted to $793.7 million in FY2024, which was up 11.32% from $713.0 million recorded in FY2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Accumulated Expenses peaked at $793.7 million during FY2024, and registered a low of $355.9 million during FY2020.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Accumulated Expenses value was $713.0 million (recorded in 2023), while the average stood at $684.1 million.
  • Data for Alnylam Pharmaceuticals' Accumulated Expenses shows a peak YoY soared of 80.48% (in 2020) over the last 5 years.
  • Alnylam Pharmaceuticals' Accumulated Expenses (Yearly) stood at $355.9 million in 2020, then grew by 11.03% to $395.2 million in 2021, then soared by 38.03% to $545.5 million in 2022, then soared by 30.72% to $713.0 million in 2023, then climbed by 11.32% to $793.7 million in 2024.